Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27482075 | 0.91 | — | — | |
| SCHEMBL14102785 | 0.90 | — | — | |
| SCHEMBL17209456 | 0.89 | — | — | |
| SCHEMBL26170089 | 0.85 | — | — | |
| SCHEMBL19321826 | 0.85 | GBA1 (0.32) | — | |
| SCHEMBL15533764 | 0.84 | CYP2D6 (0.35) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30481636 | 0.84 | HSD17B10 (0.34) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7086547 | 0.82 | GNAO1 (0.35) | — | |
| SCHEMBL24575425 | 0.82 | — | — | |
| SCHEMBL20755869 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023072197-A1 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| WO-2022002100-A1 | NOVEL BENZIMIDAZOLE COMPOUND | 微境生物医药科技(上海)有限公司 | 2022-01-06 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | CYP2D6 1819/4885SLC6A2 4739/4885SLC6A4 4763/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2D6 2910/4885SLC6A2 4748/4885SLC6A4 4818/4885 |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | OXA1L, CYP2C19, CBR3 | CYP2D6 10/4885SLC6A2 3564/4885SLC6A4 4323/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | CYP2D6 2910/4885SLC6A2 4748/4885SLC6A4 4818/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SLC6A2 4857/4885SLC6A4 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.